From the Guidelines
Trelegy Ellipta is the best option for seniors due to its triple therapy combination, ease of use, and reduced risk of mortality, as evidenced by recent studies such as the IMPACT and ETHOS trials 1. The benefits of Trelegy Ellipta for seniors can be broken down into several key points:
- Simplified treatment regimen: Trelegy Ellipta combines three medications in one inhaler, making it easier for seniors to manage their condition and improve adherence to their treatment plan.
- Reduced risk of mortality: The IMPACT and ETHOS trials have shown that triple therapy, such as that found in Trelegy Ellipta, can reduce the risk of mortality in patients with COPD, particularly those with a history of frequent and/or severe exacerbations 1.
- Improved quality of life: By reducing inflammation, relaxing airway muscles, and improving breathing, Trelegy Ellipta can help seniors with COPD or asthma to manage their symptoms and improve their overall quality of life.
- Ease of use: The Trelegy Ellipta device is designed to be easy to use, with a large lever and dose counter, making it more manageable for older adults with arthritis or reduced dexterity. Some potential side effects to be aware of include:
- Throat irritation
- Hoarseness
- Increased risk of pneumonia However, the benefits of Trelegy Ellipta, including its ability to reduce the risk of mortality and improve quality of life, make it a valuable treatment option for seniors with respiratory conditions like COPD or asthma, as supported by the 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD 1.
From the Research
Benefits of Trillegy Ellipta for Seniors
- Trillegy Ellipta, a single-inhaler triple therapy, has been shown to be effective in improving lung function and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) 2, 3, 4.
- The therapy combines fluticasone furoate, umeclidinium, and vilanterol, which work together to reduce inflammation, open airways, and improve breathing.
- Studies have demonstrated that Trillegy Ellipta can improve health status and symptoms in patients with COPD, including those with frequent exacerbations 2, 4.
- The medication has also been shown to be safe and effective in older adults (≥65 years) with COPD, with similar efficacy and safety profiles compared to younger patients (<65 years) 5.
Comparison to Other Treatments
- Trillegy Ellipta has been compared to other single-inhaler triple therapies, such as budesonide/glycopyrrolate/formoterol fumarate, and has been shown to have a lower rate of moderate-severe COPD exacerbations and a lower risk of all-cause mortality 6.
- The medication has also been shown to be effective in reducing exacerbations and improving lung function compared to dual therapies 3, 4.
Real-World Effectiveness
- Real-world studies have demonstrated the effectiveness of Trillegy Ellipta in improving health status and reducing exacerbations in patients with COPD 4, 6.
- The medication has been shown to be effective in patients with a range of disease severity and comorbidities, making it a valuable treatment option for seniors with COPD.